Challenges in Colorectal Cancer, 2nd Edition
March 2008, Wiley-Blackwell
Colorectal cancer is one of the most common forms of cancer in the US and Europe. Thousands of people are diagnosed with the disease every year and nearly half of these die as a result. As colorectal cancer is curable when detected early, a significant proportion of these deaths could be prevented by earlier diagnosis.
Much has changed since the publication of the first edition of
this book in 2001: introduction of screening programs, improved
diagnosis and surgery for rectal cancer, and advances in adjuvant
and palliative medical therapy to name but a few.
Challenges in Colorectal Cancer provides the most
up-to-date information on the new and emerging treatments. The
second edition looks at the total patient management of this
condition and is aimed at the entire medical team caring for those
with colorectal cancer. It also contains the latest guidelines on
epidemiology and prevention of colorectal cancer, and the
application of molecular genetics.
The expanded international editor team present advice on surgical management, including new laparoscopic and endoscopic techniques and the role of the pathologist. They also review hot topics in colorectal cancer treatment, including the role of radiotherapy, options for chemotherapy and new developments in vaccines and immunotherapy.
1 Richard Nelson.
Does lifestyle cause colorectal cancer?.
2 Robert Steele.
Screening for colorectal cancer – who, when, and how?.
3 Phil Quirke.
What can the pathologist tell the multidisciplinary team about rectal cancer resection?.
4 Brendan Morgan and John H. Scholefield.
MRI-directed rectal cancer surgery.
5 Pierre J. Guillou.
Minimally invasive surgery – where are we? Laparoscopic surgery for cancer of the colon and rectum.
6 Theodore J. Saclarides.
Minimally invasive surgery – where are we? Is there a role for TEM?.
7 Seung-Yong Jeong, David Chessin, Susan Ritchie, John H. Scholefield, and Jose G. Guillem.
What is the best strategy for the management of hereditary colorectal cancer?.
8 Rachel Cooper and David Sebag-Montefiore.
Adjuvant radiotherapy and chemoradiotherapy in the treatment of rectal cancer.
9 George P. Kim and Axel Grothey.
Current challenges in the adjuvant therapy of colon cancer.
10 Jill Dean.
The role of the colorectal nurse specialist in the management of colorectal cancer.
11 Julia Jessop and Ian Daniels.
The role of the multidisciplinary team in the management of colorectal cancer.
12 John Northover and Chris Byrne.
Follow-up after colorectal cancer resection: Is it worthwhile?.
13 Axel Grothey.
Chemotherapy of advanced colorectal cancer.
14 Timothy G. John and Myrddin Rees.
Surgery for metastatic disease in colorectal cancer.
15 Melanie Jefferson and Ilora Finlay.
Palliative care of the colorectal cancer patient.
16 Anthony E l–Khoueiry and Heinz-Josef Lenz.
Future directions in the oncological treatment of colorectal cancer.
Professor Herand Abcarian MD FACS, Turi Josefsen
Professor and Chairman of the Department of Surgery, University of
Illinois College of Medicine at Chicago, USA.
Professor Tim Maughan, Professor of Cancer Studies at the
University of Wales, College of Medicine, and Consultant Clinical
Oncologist at the Velindre Hospital Swansea. Also Chairman of the
All Wales Cancer Network.
Professor Axel Grothey, Mayo Clinic, USA (formerly Professor of Medicine and Oncology at Martin Luther University, Halle, Germany).
- The expanded international editor team reflects the increasing
global significance of this disease
- Includes the latest guidelines on epidemiology and prevention
of colorectal cancer, such as the application of molecular
genetics, and the new strategies for screening
- Presents didactic advice on surgical management, including new
laparoscopic and endoscopic techniques and the role of the
- Gives detailed oncological management, including the role of radiotherapy, options for chemotherapy and new developments in vaccines and immunotherapy
Colorectal Disease, 2007
"A good book looking at the total management of patients with this condition and aimed at the entire medical team caring fro those with colorectal cancer."
Digestive and Liver Disease, 2007
From a review of the first edition:
“More knowledge of molecular biology, better definition of risk groups, better screening, further development of risk- oriented combination therapy, and more meticulous surgery may yield much higher cure rates for colon and rectal cancer. Scholefield’s book is one of the best starting points for a journey through the world of established, new, and evolving treatments for these diseases.”
New England Journal of Medicine, September 2000
"Robert W Beart, Jr., states in the foreword that this book provides an "up-to-date record of the rapidly evolving alternatives" in chapters which span the gamut from prevention through palliation. It is written for subspecialist physicians, nurses, and other members of the medical team. The emphasis throughout is providing this team with concrete, useful information. Although the authors are predominantly from the U.K., European and American issues are identified throughout." (Carol Scott-Conner, MD, PhD, MBA, @Doody's Review Service)